Sign up to access all valuation multiples
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
1997
170
LTM Revenue $80.8M
LTM EBITDA $43.2M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of October 2025, ChemoMetec reported last 12-month revenue of $80.8M and EBITDA of $43.2M.
In the same period, ChemoMetec generated $63.0M in LTM gross profit and $31.2M in net income.
See ChemoMetec valuation multiples based on analyst estimatesIn the most recent fiscal year, ChemoMetec reported revenue of $77.3M and EBITDA of $40.9M.
ChemoMetec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ChemoMetec valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $80.8M | XXX | $77.3M | XXX | XXX | XXX |
| Gross Profit | $63.0M | XXX | $72.7M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | $43.2M | XXX | $40.9M | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 53% | XXX | XXX | XXX |
| EBIT | $39.0M | XXX | $36.9M | XXX | XXX | XXX |
| EBIT Margin | 48% | XXX | 48% | XXX | XXX | XXX |
| Net Profit | $31.2M | XXX | $29.1M | XXX | XXX | XXX |
| Net Margin | 39% | XXX | 38% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ChemoMetec has current market cap of DKK 13.8B (or $2.2B), and EV of DKK 13.4B (or $2.1B).
As of October 31, 2025, ChemoMetec's stock price is DKK 792 (or $124).
See ChemoMetec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $2.2B | XXX | XXX | XXX | XXX | $1.79 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialChemoMetec's trades at 29.8x EV/Revenue multiple, and 59.0x EV/EBITDA.
See valuation multiples for ChemoMetec and 15K+ public compsAs of October 31, 2025, ChemoMetec has market cap of $2.2B and EV of $2.1B.
Equity research analysts estimate ChemoMetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ChemoMetec has a P/E ratio of 69.0x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 26.0x | XXX | 29.8x | XXX | XXX | XXX |
| EV/EBITDA | 48.6x | XXX | 59.0x | XXX | XXX | XXX |
| EV/EBIT | 53.8x | XXX | 66.3x | XXX | XXX | XXX |
| EV/Gross Profit | 33.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 69.0x | XXX | 85.4x | XXX | XXX | XXX |
| EV/FCF | 96.7x | XXX | 117.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChemoMetec's last 12 month revenue growth is 15%
ChemoMetec's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
ChemoMetec's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ChemoMetec's rule of X is 91% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ChemoMetec and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | 66% | XXX | 66% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 91% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ChemoMetec acquired XXX companies to date.
Last acquisition by ChemoMetec was XXXXXXXX, XXXXX XXXXX XXXXXX . ChemoMetec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was ChemoMetec founded? | ChemoMetec was founded in 1997. |
| Where is ChemoMetec headquartered? | ChemoMetec is headquartered in Denmark. |
| How many employees does ChemoMetec have? | As of today, ChemoMetec has 170 employees. |
| Is ChemoMetec publicy listed? | Yes, ChemoMetec is a public company listed on CSE. |
| What is the stock symbol of ChemoMetec? | ChemoMetec trades under CHEMM ticker. |
| When did ChemoMetec go public? | ChemoMetec went public in 2006. |
| Who are competitors of ChemoMetec? | Similar companies to ChemoMetec include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of ChemoMetec? | ChemoMetec's current market cap is $2.2B |
| What is the current revenue of ChemoMetec? | ChemoMetec's last 12 months revenue is $80.8M. |
| What is the current revenue growth of ChemoMetec? | ChemoMetec revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of ChemoMetec? | Current revenue multiple of ChemoMetec is 26.0x. |
| Is ChemoMetec profitable? | Yes, ChemoMetec is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ChemoMetec? | ChemoMetec's last 12 months EBITDA is $43.2M. |
| What is ChemoMetec's EBITDA margin? | ChemoMetec's last 12 months EBITDA margin is 53%. |
| What is the current EV/EBITDA multiple of ChemoMetec? | Current EBITDA multiple of ChemoMetec is 48.6x. |
| What is the current FCF of ChemoMetec? | ChemoMetec's last 12 months FCF is $21.7M. |
| What is ChemoMetec's FCF margin? | ChemoMetec's last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of ChemoMetec? | Current FCF multiple of ChemoMetec is 96.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
